Aprea Therapeutics (NASDAQ:APRE – Get Free Report) is expected to be posting its quarterly earnings results before the market opens on Tuesday, March 25th. Analysts expect Aprea Therapeutics to post earnings of ($0.69) per share and revenue of $0.15 million for the quarter.
Aprea Therapeutics Stock Performance
APRE opened at $2.39 on Friday. The firm has a market cap of $12.99 million, a P/E ratio of -0.85 and a beta of 0.82. The firm has a 50-day moving average of $3.18 and a 200 day moving average of $3.27. Aprea Therapeutics has a fifty-two week low of $2.15 and a fifty-two week high of $6.80.
Wall Street Analyst Weigh In
Separately, HC Wainwright reaffirmed a “buy” rating and set a $20.00 price objective on shares of Aprea Therapeutics in a report on Wednesday, January 15th.
Aprea Therapeutics Company Profile
Aprea Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on developing and commercializing novel synthetic lethality-based cancer therapeutics that targets DNA damage response pathways. Its lead product candidate is the ATRN-119 that is in Phase I clinical trials for treating advanced solid tumors.
Featured Stories
- Five stocks we like better than Aprea Therapeutics
- Transportation Stocks Investing
- Why Williams-Sonoma Will Hit Fresh Highs in 2025
- Special Purpose Acquisition Company (SPAC) What You Need to Know
- Alphabet Stock Becomes a Low-Risk, High-Reward Play
- Mastering Discipline: Overcoming Emotional Challenges In Trading
- Affirm Stock: Should You Buy the Dip After Walmart Setback?
Receive News & Ratings for Aprea Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aprea Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
